Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Research Study Looking at the Effect of Semaglutide on the Immune System and Other Biological Processes in People With Alzheimer's Disease
- Conditions
- Alzheimers Disease
- Interventions
- Drug: Placebo
- First Posted Date
- 2023-06-07
- Last Posted Date
- 2025-01-03
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05891496
- Locations
- 🇮🇹
Fondazione Santa Lucia IRCCS, Roma, Italy
🇨🇦Memory Program, Toronto, Ontario, Canada
🇸🇪Karolinska Universitetssjukhuset, Huddinge, Stockholm, Sweden
Research Study Looking at How Well Semaglutide Tablets Taken Once Daily Work in Chinese Adults Who Are Above a Healthy Weight Range (OASIS 3)
- First Posted Date
- 2023-06-06
- Last Posted Date
- 2025-03-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 200
- Registration Number
- NCT05890976
- Locations
- 🇨🇳
Peking University People's Hospital-Endocrinology, Beijing, Beijing, China
🇨🇳Beijing Friendship Hospital, Capital Medical University-Endocrinology, Beijing, Beijing, China
🇨🇳Chongqing University Three Gorges Hospital, Chongqing, Chongqing, China
A Research Study Looking at How Safe it is to Switch From Emicizumab to Mim8 in People With Haemophilia A (FRONTIER 5)
- Conditions
- Haemophilia AHaemophilia A With Inhibitors
- Interventions
- Drug: NNC0365-3769 (Mim8) PPX
- First Posted Date
- 2023-05-30
- Last Posted Date
- 2024-11-18
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 61
- Registration Number
- NCT05878938
- Locations
- 🇩🇪
Vivantes Klinikum am Friedrichshain - Innere Medizin - Angiologie und Hämostaseologie, Berlin, Germany
🇩🇪Universitätsklinikum Bonn - Institut für Experimentelle Hämatologie, Bonn, Germany
🇺🇸Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
A Study to Characterize the Prevalence of Overweight and Obesity Among Patients With Established Cardiovascular Disease
- Conditions
- OverweightObesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-05-24
- Last Posted Date
- 2024-07-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5360
- Registration Number
- NCT05873660
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Madrid, Spain
A Research Study of a New Medicine NNC0519-0130 in Japanese and Non-Japanese Men
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 22
- Registration Number
- NCT05870670
- Locations
- 🇯🇵
SOUSEIKAI Sumida Hospital, Tokyo, Japan
A Study to Evaluate Safety of Exposure to Wegovy During Pregnancy
- Conditions
- PregnancyObesityOverweight
- Interventions
- Other: No Intervention
- First Posted Date
- 2023-05-23
- Last Posted Date
- 2024-12-31
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 728
- Registration Number
- NCT05872022
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, London, United Kingdom
A Study Using Flash Glucose Measurements for a New Once-weekly Insulin (Insulin Icodec) in People With Type 2 Diabetes Who Have Not Used Insulin Before (ONWARDS 9)
- First Posted Date
- 2023-04-21
- Last Posted Date
- 2025-03-06
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 51
- Registration Number
- NCT05823948
- Locations
- 🇺🇸
Amarillo Medical Specialists, Amarillo, Texas, United States
🇺🇸Accellacare_NC, Wilmington, North Carolina, United States
🇺🇸Desert Oasis Hlthcr Med Group, Palm Springs, California, United States
A Research Study to See How a New Weekly Insulin, Insulin Icodec When Given Along With Semaglutide Helps in Reducing the Blood Sugar Level in Patients With Type 2 Diabetes
- Conditions
- Diabetes Mellitus, Type 2
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 148
- Registration Number
- NCT05813912
- Locations
- 🇲🇾
Hospital Universiti Kebangsaan Malaysia, Cheras, Kuala Lumpur, Malaysia
🇲🇾Universiti Teknologi MARA, Sungai Buloh Campus, Sungai Buloh, Selangor, Malaysia
🇹🇭King Chulalongkorn Memorial Hospital, Bangkok, Thailand
A Research Study to See How Well CagriSema Helps People in East Asia With Excess Body Weight Lose Weight
- Conditions
- Obesity or Overweight
- Interventions
- First Posted Date
- 2023-04-14
- Last Posted Date
- 2025-04-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 331
- Registration Number
- NCT05813925
- Locations
- 🇯🇵
Yao Tokushukai General Hospital, Yao-shi, Osaka, Japan
🇯🇵Seino Internal Medicine Clinic, Koriyama-shi, Fukushima, Japan, Japan
🇯🇵Tsuruma Kaneshiro Diabetes Clinic, Yamato-shi, Kanagawa, Japan
A Research Study Looking at How Cagrilintide Works on the Heart Rhythm in Healthy Participants
- Conditions
- Obesity
- Interventions
- First Posted Date
- 2023-04-07
- Last Posted Date
- 2024-11-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 107
- Registration Number
- NCT05804162
- Locations
- 🇩🇪
Parexel International GmbH, Berlin, Germany